Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reviews Ayurveda and Yoga as holistic approaches for managing PCOS, highlighting their potential efficacy in restoring hormonal balance and improving reproductive health but reports no new clinical results.

In this study, a case of Alopecia totalis was treated using cupping therapy along with ayurvedic treatments, suggesting that the combination may be effective due to the herbs' synergistic effects and cupping's immunostimulant activity.

This article discusses how Indian ergonomics or yoga asanas can help hair transplantation surgeons maintain physical and mental fitness, but it reports no new clinical outcomes.

This review discusses the molecular mechanisms of androgenetic alopecia and evaluates current and potential treatments, highlighting the limitations of minoxidil and finasteride and exploring newer approaches like growth factors and cytokines, topical 5-alpha-reductase inhibitors, and platelet-rich plasma injections as more effective and safer alternatives.

This review discusses advancements in plant cell culture technology for producing potent natural cosmetic ingredients and reports no new experimental results.

In this study, researchers found that in mice, gonadal hormones and biological sex do not affect the expression of SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in the respiratory tract, regardless of disease state.

This report details a case of a 58-year-old male diagnosed with erosive pustular dermatosis of the scalp, which improved following 3-5 weeks of treatment with topical clobetasol proprionate.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that chitosan nanofibrillar scaffolds accelerated skin wound healing in mice by enhancing cell adhesion, proliferation, and regeneration of epidermis and dermis compared to other forms.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.

Alopecia areata patients often have eczema, thyroid issues, vitamin-D deficiency, and anemia.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

This study found that the emotional impact of alopecia areata is significant, but it may not correlate directly with the extent of hair loss since some individuals adapt to the condition.

This review examines complementary and alternative medicine for alopecia and finds limited support from robust clinical trials, highlighting the need for standardized studies to evaluate efficacy and safety.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

This review found topical ketoconazole to be highly effective against Malassezia-related skin conditions, though other treatments may outperform it for Tinea and Candida infections.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

This study found that parental reports of neuro-psychiatric disorders were higher in children exposed to maternal anti-Ro antibodies, yet these differences compared to controls were not statistically significant.

This review discusses chemotherapy-induced alopecia, highlighting its pathogenesis, clinical patterns, and current therapeutic approaches, with no new clinical results reported.

This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.

This review discusses medication-induced gray hair repigmentation, highlighting that certain anti-inflammatory drugs and melanogenesis stimulators can cause diffuse repigmentation, though evidence remains low-quality and these medications are not currently indicated for this purpose.